Introduction: Managing patients with obstructing locally advanced rectal cancer (LARC) is challenging. A planned stoma is a feasible approach; however, it may result in treatment delay.1,2 The emergence of new drugs and the identification of novel molecular pathways have the potential to revolutionize the management and treatment response of these patients.3 The authors presented a case of obstructing LARC managed with a staged multimodal approach based on immune neoadjuvant therapy (NAT) and stoma-resection-reversal strategy.4
Wang et al. (Thu,) studied this question.